Produktinformation
- Ar-H 053591
- Biie-0246
- Cyclopentaneacetamide, N-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-
- N-[(1S)-4-[(Aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]cyclopentaneacetamide
- N5-(diaminomethylidene)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N2-[(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-L-ornithinamide
BIIE 0246 is a neuroactive peptide that is involved in the regulation of neuronal death. It has been shown to be a metabolic regulator, with effects on the epididymal adipose tissue, and also an immunomodulator. BIIE 0246 has been shown to induce autoimmune diseases in vivo by inhibiting the production of inflammatory cytokines. It has been used as an inhibitor of enzymes such as phospholipase A2, which are involved in inflammation and lipid metabolism. BIIE 0246 also inhibits the angiotensin II type 1 receptor (AT1), which regulates blood pressure and cardiac function. This drug also has locomotor activity-inducing effects, resulting in increased motor activity and reduced immobility time on a rotarod test, as well as memory-enhancing properties that have been observed through changes in hippocampal formation activity.
Chemische Eigenschaften
Technische Anfrage zu: 3D-WJA14655 BIIE 0246
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.